Navigation Links
SIGA Technologies Files Notice of Appeal in PharmAthene Litigation
Date:6/12/2012

NEW YORK, June 12, 2012 /PRNewswire/ -- SIGA Technologies, Inc. (NASDAQ: SIGA), a company specializing in the development of pharmaceutical agents to fight pathogens capable of use as bioweapons, today announced that it has filed a Notice of Appeal seeking to overturn the Delaware Chancery Court's May 31, 2012 final order and judgment in the litigation that PharmAthene, Inc. commenced in December 2006. 

Dr. Eric A. Rose, SIGA's Chief Executive Officer, commented, "We look forward to the opportunity to show why the Chancery Court's rulings were made in error."

While SIGA believes its appellate arguments are meritorious, no assurance can be given that the appeal will be successful.  

About SIGA Technologies, Inc.
In the United States and around the world, populations face a serious but unmet need for drugs to protect against potentially catastrophic emerging viral pathogens and biological weapons of mass destruction. SIGA Technologies, Inc. is a pharmaceutical company specializing in the development and commercialization of therapeutic solutions for some of the most lethal disease causing pathogens in the world - smallpox, Ebola, dengue, Lassa fever and other dangerous viruses. Our business is to discover, develop, manufacture and successfully commercialize drugs to prevent and treat these high priority threats. Our mission is to disarm dreaded viral diseases and create robust, modern biodefense countermeasures. For more information about SIGA, please visit SIGA's web site at www.siga.com.

The SIGA Technologies, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=4504

Forward-looking Statements
This press release contains certain "forward-looking statements"' within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements regarding developments in our ongoing litigation with PharmAthene, Inc.  Such forward-looking statements are subject various known and unknown risks and uncertainties and SIGA cautions you that any forward-looking information provided by or on behalf of SIGA is not a guarantee of future performance. SIGA's actual results could differ materially from those anticipated by such forward-looking statements due to a number of factors, some of which are beyond SIGA's control, including, but not limited to, (i) the risk that potential products that appear promising to SIGA or its collaborators cannot be shown to be efficacious or safe in subsequent pre-clinical or clinical trials, (ii) the risk that SIGA or its collaborators will not obtain appropriate or necessary governmental approvals to market these or other potential products, (iii) the risk that SIGA may not be able to obtain anticipated funding for its development projects or other needed funding, (iv) the risk that SIGA may not be able to secure funding from anticipated government contracts and grants, (v) the risk that SIGA may not be able to secure or enforce sufficient legal rights in its products, including patent protection, (vi) the risk that any challenge to SIGA's patent and other property rights, if adversely determined, could affect SIGA's business and, even if determined favorably, could be costly, (vii) the risk that regulatory requirements applicable to SIGA's products may result in the need for further or additional testing or documentation that will delay or prevent seeking or obtaining needed approvals to market these products, (viii) the risk that one or more protests could be filed and upheld in whole or in part or other governmental action taken, in either case leading to a delay of performance under the BARDA Contract or other governmental contracts, (ix) the risk that the BARDA Contract is modified or cancelled at the request or requirement of the U.S. government, (x) the risk that the adverse portions of the post-trial decision by the Delaware Chancery Court in the litigation brought by PharmAthene, Inc. will be upheld in further proceedings, including any appeal, or that the favorable portions will be modified, (xi) the risk that the volatile and competitive nature of the biotechnology industry may hamper SIGA's efforts to develop or market its products, (xii) the risk that the changes in domestic and foreign economic and market conditions may adversely affect SIGA's ability to advance its research or its products, and (xiii) the effect of any change to federal, state, or foreign regulation, including drug regulation and international trade regulation, on SIGA's businesses. More detailed information about SIGA and risk factors that may affect the realization of forward-looking statements, including the forward-looking statements in this presentation, is set forth in SIGA's filings with the Securities and Exchange Commission, including SIGA's Annual Report on Form 10-K for the fiscal year ended December 31, 2011, and in other documents that SIGA has filed with the SEC. SIGA urges investors and security holders to read those documents free of charge at the SEC's Web site at http://www.sec.gov. Interested parties may also obtain those documents free of charge from SIGA. Forward-looking statements speak only as of the date they are made, and except for our ongoing obligations under the United States of America federal securities laws, we undertake no obligation to publicly update any forward-looking statements whether as a result of new information, future events or otherwise.

Contact: 
KCSA Strategic Communications 
Todd Fromer / Robert Fink 
212-896-1215 / 1236 
Tfromer@kcsa.com / Rfink@kcsa.com

 


'/>"/>
SOURCE SIGA Technologies, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Life Technologies and Cellular Dynamics International Partner for Global Commercialization of Novel Stem Cell Technologies
2. Biodel Obtains Exclusive License to Aegis Therapeutics Technologies for Development and Commercialization of Glucagon Pharmaceutical Formulations
3. IDEV Technologies Introduces SurePath™ Guidewires
4. Acuo Technologies Grows European Business and Achieves Successful Connectathon Results in Bern, Switzerland
5. Life Technologies and OpGen Sign Collaborative Agreement to Leverage Ion Torrent and Whole Genome Mapping Technologies
6. Breathe Technologies Non-Invasive Open Ventilation (NIOV™) System Receives Medical Design Award
7. Patient Safety Technologies Reports First Quarter 2012 Results
8. MedClean Technologies Announces 2011 Results
9. Global Ablation Technologies Market (2011-2016) - By Application and Devices in Radiofrequency, Cryoablation, Microwave, Ultrasound, Hydrothermal, Radiation, Electrical, Light/Laser and Hydromechanical - Global Trends & Competitive Analysis
10. BioStorage Technologies to Lead Discussion on the Value of a Comprehensive Sample Management Strategy
11. ICU Medical, Inc. Plans to "Vigorously Seek to Collect Damages" in wake of Patent Infringement Victory Over RyMed Technologies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2016)... 27, 2016 Elekta today announced ... will be the focal point of seven scientific presentations ... Society for Radiotherapy & Oncology, taking place April 29 ... state-of-the-art radiotherapy system and a high-field MRI scanner with ... the patient,s anatomy in real time. The MR-linac is ...
(Date:4/27/2016)... , April 27, 2016  Bayer Animal Health ... senior from the University of Florida College of ... Bayer Excellence in Communication Award (BECA). Brittany was ... were awarded a total of $70,000 in scholarship ... four years, Bayer has provided a total of ...
(Date:4/27/2016)... , April 27, 2016 ... USD 2.14 billion by 2022, according to a ...      (Logo: http://photos.prnewswire.com/prnh/20150105/723757 ) , ... affecting the efficiency and accuracy delivered by the ... demand for novel urinalysis instruments and consumables. For ...
Breaking Medicine Technology:
(Date:4/29/2016)... ... 29, 2016 , ... Regenerative Medicine Solutions (RMS) scored 94.8124 out ... earning them second place for Tampa’s Best Places to Work. They were ranked in ... a great accomplishment for our team,” says RMS Human Resources Manager Irene Miller. “We ...
(Date:4/29/2016)... San Rafael, CA (PRWEB) , ... April 29, 2016 , ... ... a week long softball camp from July 24th – 27th for girls aged 10-18. ... The camp is held at the beautiful Clark V. Whited Complex, one of the ...
(Date:4/29/2016)... ... 29, 2016 , ... HEALTHCAREfirst , the leading provider ... Deyta Analytics, recently announced the recipients of the fourth annual Hospice Honors, a ... from the caregiver’s point of view. The official list of recipients was unveiled ...
(Date:4/29/2016)... ... April 29, 2016 , ... Intellitec ... held May 16th to 18th at the Broward County Convention Center. The event ... to collaborate on best practices in public facility management. Intellitec Solutions will highlight ...
(Date:4/29/2016)... ... April 29, 2016 , ... Yisrayl Hawkins, Pastor and ... highlighting inconsistencies of adding BC and AD, saying it is time to set the ... After Christ. Yisrayl says this simply cannot possibly be true and offers explanation. , ...
Breaking Medicine News(10 mins):